EUVIMEDEUVIMED entdecken
Crossref

The additive value of 68Ga-RM26 PET/CT to 68Ga-PSMA−617 PET/CT in assessing Post-treatment outcomes of ARSIs in mCRPC patients

Xuhao Liu, Lin Qi, Xiaomei Gao, Shuo Hu, Yongxiang Tang, Minfeng Chen, Yi Cai iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025-12 · 53 (1) · 218-230

DOI: 10.1007/s00259-025-07407-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 16.06.2025. Verfasst von Xuhao Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospit…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Castration-Resistant, Heterocyclic Compounds, 1-Ring, Dipeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Outstanding Youth Fund Project of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Besides its potential as a PET/CT tracer, the Gastrin-Releasing Peptide Receptor (GRPR) has been shown to predict the prognosis of Prostate Cancer (PCa). Herein, we aimed to evaluate the additive ability of 68Ga-RM26 PET/CT as a tracer to predict the prognosis of patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) following Androgen Receptor Signal Inhibitors (ARSIs) therapy. METHODS: This retrospective single-center study involved patients who underwent both 68Ga-PSMA-617 PET/CT and 68Ga-RM26 PET/CT scans. Based on the GRPR status of their lesions (positive/negative), the patients were stratified into two cohorts, and their actual prognosis was assessed by comparing their maximum Prostate-Specific Antigen (PSA) response rates and Progression-Free Survival (PFS) durations following ARSI therapy. RESULTS: This study involved 44 patients. Among them, 41 and 23 showed PSMA uptake and GRPR uptake, respectively, with 3 exhibiting GRPR uptake alone. The GRPR + group had an median PSA response rate of 37.78% and a median PFS duration of 8.9 months, both of which were significantly lower than those of GRPR- patients, whose corresponding values were 69.39% and 14.37 months, respectively. According to the multivariate analysis results, GRPR status, distant Lymph Node Metastasis (LNM) and PSMA SUVmax of bone metastases lesions were significant predictors of the PSA response rate. Furthermore, the GRPR status and PSMA SUVmax of regional lymph node metastases were significant predictors of PFS. CONCLUSION: Compared to GRPR- patients, mCRPC patients with GRPR + lesions exhibited a lower median maximum PSA response rate and a shorter median PFS duration following ARSI treatment, implying a poorer response to therapy and relatively worse prognosis in the latter subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantHeterocyclic Compounds, 1-RingDipeptidesHumansMaleAgedMiddle AgedGallium RadioisotopesRetrospective StudiesGallium IsotopesTreatment OutcomeAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

ARSIGRPRPSMAPrognosismCRPC

Substanzen

Gallium RadioisotopesGallium IsotopesHeterocyclic Compounds, 1-RingDipeptidesPSMA-617gallium 68 PSMA-11Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. hushuo2018@163…
  • Department of Nuclear Medicine, National Clinical Research Center for Geriatric Disorders, Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, No.87 Xia…
  • Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. xyyf0401@qq.co…
  • Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. chenminfeng1999@csu.edu…

ORCID-Profile: Yi Cai

Förderung

  • Outstanding Youth Fund Project of Hunan Province

Zitieren

APA

Liu, X., Qi, L., Gao, X., Hu, S., Tang, Y., Chen, M., & Cai, Y. (2025). The additive value of 68Ga-RM26 PET/CT to 68Ga-PSMA−617 PET/CT in assessing Post-treatment outcomes of ARSIs in mCRPC patients. European Journal of Nuclear Medicine and Molecular Imaging, 53(1), 218-230. https://doi.org/10.1007/s00259-025-07407-8

Vancouver

Liu X, Qi L, Gao X, Hu S, Tang Y, Chen M, et al. The additive value of 68Ga-RM26 PET/CT to 68Ga-PSMA−617 PET/CT in assessing Post-treatment outcomes of ARSIs in mCRPC patients. European Journal of Nuclear Medicine and Molecular Imaging. 2025;53(1):218-230. doi:10.1007/s00259-025-07407-8

BibTeX
@article{Liu2025,
  author = {Liu, Xuhao and Qi, Lin and Gao, Xiaomei and Hu, Shuo and Tang, Yongxiang and Chen, Minfeng and Cai, Yi},
  title = {The additive value of 68Ga-RM26 PET/CT to 68Ga-PSMA−617 PET/CT in assessing Post-treatment outcomes of ARSIs in mCRPC patients},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {218--230},
  doi = {10.1007/s00259-025-07407-8}
}
Kostenlos starten →